Objective: WHO issued a PHEIC revocation status for COVID-19. Prevention efforts with vaccination must still be carried out for long-term plans due to decreased effectiveness and virus mutations. The most severe impact was felt by the elderly, with 49.40% of the total 151,951 deaths recorded in Indonesia due to COVID-19. The aim of this research was to determine the determinants factor of receiving the COVID-19 booster vaccine for the elderly in Bogor City. Methods: uses the document review method sourced from the website www.covid-19.go.id and qualitatively uses the Social Ecological Model and the Health Belief Model theory. Documents were reviewed from 2020 to June 2023. Qualitative data were collected by selecting informants using purposive sampling and processed using the Nvivo application. Results: Based on extrinsic factors, there were 40 policies issued by the government specifically regarding the COVID-19 vaccine but have not been issued in Bogor City. The role of the community, organizations, and elderly families has not been maximized because of low knowledge regarding vaccines, dissemination of information on the COVID-19 vaccine still in general, and some families have not allowed the elderly to be vaccinated. Based on intrinsic factors, it shows that perceived susceptibility, perceived barriers, and cues to action have an influence on the acceptance of the COVID-19 vaccine in the elderly in Bogor City. Conclusion: The determinants of the achievement of the COVID-19 booster vaccine in the elderly, there is no policy that has been issued specifically for the elderly in Bogor City. Community, organizations and elderly families have not played a sufficient role in implementing vaccinations and the elderly have low knowledge about vaccines, remote vaccine locations, unpleasant side effects after being vaccinated, and family directions that are not fully supportive.
21 March 2023 in Biomedical and Pharmacology Journal
Diabetes is a disease that can reduce the quality of life of patients and lead to death. Based on Indonesian Basic Health research, the prevalence of diabetes mellitus has increased over several years. Breadfruit leaves contain antioxidant compounds that can lower blood sugar by inhibiting glucose transport in the gastrointestinal tract and stimulating insulin secretion in pancreatic beta cells. The study aimed to assess the effect of giving Breadfruit Leaf Extract on reducing Fasting Blood Sugar among type 2 Diabetes Mellitus Patients. The study used a quasi-experiment study with a randomized pretest-posttest, design with the control group. It involved 39 outpatients for type 2 diabetes mellitus at Biru Public Health Center of Bone Regency, who had suffered from Diabetes for 1-4 years. The sample was divided into 2 groups by simple random sampling, 19 respondents for the intervention group and 20 respondents for the control group. Data collected were the socio-demographic characteristics and fasting blood sugar levels. In the intervention group, breadfruit leaf capsules were given at a dose of 500 mg 1x1 for 21 days, while the control group was only given health education. The data were analyzed using the Chi-Square test, paired t-test, independent t-test, Wilcoxon Signed Rank Test, and Mann-Whitney. The majority of respondents aged 46-55 years were 53.8% in both groups, 74.4% were female, while the majority of BMI status had normal nutritional status as much as 41%. There was a change in FBS levels in the intervention group before (263.31 ± 134.43) and after (174.84 ± 84.99) intervention (p-value = 0.000). there was a change in FBS levels in the group before (181.35±91.36) and after (147.45 ±79.25) intervention (p-value = 0.001). it is known that there is a significant difference in changes in fasting blood sugar levels of patients with diabetes mellitus in the intervention group (-88.47±88.01) and the control group (-33.90±53.53) with (p-value = 0.024). The test results show that the content of flavonoids and other non-nutritive substances in breadfruit leaves has an effect on lowering the FBS of patients with diabetes mellitus and can be used as an alternative medicine in patients with diabetes mellitus.
Rice Bran Oil (RBO) is an abundant food source in Indonesia. RBO contains high levels of monounsaturated fatty acids and rich in antioxidants. However, clinical trials on this material are still very limited. This research aims to assess the differences of effect of rice bran oil (RBO) and olive oil (OO) on lipid profile alteration of hypercholesterolemia junior high school teachers. This study used a quasi-experimental method with a non-randomized pre-test and post-test design. A total of 28 junior high school teachers in the Tamalanrea District of Makassar City who experienced hypercholesterolemia were recruited in this study and were divided into 2 groups. The two groups were at different research locations and received different interventions. The intervention group was given rice bran oil (30 ml/day) while the control group was given olive oil (30 ml/day) for 30 days. The pair t test was used to determine the difference in lipid profile before and after giving RBO and OO. The analysis was continued by comparing the results in the two groups using the independent t test. The level of confidence was set at 95% with a significance value less than 0.05 (p <0.05). After giving RBO for 30 days, the results were a decrease in total cholesterol by 4.59%, triglycerides by 15.8%, LDL by 4.87%, but HDL levels also decreased, although in insignificant amounts (3.41%). Meanwhile, giving OO as a control reduced total cholesterol by 5.04% and triglycerides by 28.2%. In addition, there was also a slight increase in HDL levels by 0.45%, in contrast to LDL levels which did not show any difference at all. At the end of the study of the four lipid profile parameters observed, significant improvements were observed in the reduction of total cholesterol and triglyceride levels significantly after administration of RBO and OO (p 0.05). From this study, we can conclude that rice bran oil and olive oil have the same effect in improving lipid profiles by significantly lowering total cholesterol and triglyceride levels.
Constipation is one of the 60% of gastrointestinal discomforts in pregnancy. WHO (2018) states that 11-38% of pregnancies will experience constipation. It takes laxative substances that stimulate peristaltic movement of the intestinal wall, such as aloe vera. However, it contains a teratogenic component for pregnant women, namely aloin. The study aims to determine the effect of aloe vera tea as a treatment for constipation and test fetal weight growth's safety during organogenesis. Methods: This research is an experimental study, a laboratory pre-clinical study using a pre-post test randomized control group design in-vivo method. Against 24 pregnant mice constipated by induced oral extract of gambier 1 ml. Results: The control group intervention (Dulcolax 0.1 ml/20grBB) had a higher mean frequency than the aloe vera tea treatment. The results of the ANOVA test of 0.013<0.05 showed a significant difference between the four groups after five days. The category of the fastest onset of action of laxatives was shown in K3 (aloe vera tea dose of 0.2gr/20grBB) at 03:08 minutes compared to the control group (Dulcolax 0.1gr/20grBB) at 04:35 minutes. The ANOVA test of 0.0000.05). Conclusion: Dulcolax 0.1 ml and aloe vera tea 0.2gr/20grBB effectively increased the frequency of defecation in mice. Aloe vera tea 0.2gr/20grBB was very effective, with the fastest onset of laxative action compared to the control group. Aloe vera tea affects fetal growth in the form of a decrease in body weight at the highest dose of 0.4gr/20grBB. Suggestion: A dose of 0.2 grams of aloe vera tea is recommended to be converted to a human dose as an effective measure for treating constipation in pregnant women.